{"url_path":"/sec/repl/8-k/2026-06-26/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1737953/0001104659-26-078009-index.html","accession_number":"0001104659-26-078009","cik":"0001737953","ticker":"REPL","issuer_name":"Replimune Group, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737953/0001104659-26-078009-index.html","primary_entity_key":"0001737953","primary_entity_name":"Replimune Group, Inc."},"word_count":157,"has_tables":true,"body_markdown":"**Item 7.01****Regulation FD Disclosure.**\n\n \n\nOn June 26, 2026, Replimune\nGroup, Inc. (the “Company”) issued a news release announcing that the U.S. Food and Drug Administration has accepted for review\nthe resubmission of the Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment\nof advanced melanoma. A copy of such news release is furnished as Exhibit 99.1\nto this Current Report on Form 8-K.\n\n \n\nIn accordance with General\nInstruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed\n“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nor otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities\nAct of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing."}